The Journal of Urology
Volume 182, Issue 2 , Pages 491-498, August 2009

Body Mass Index and Prostate Specific Antigen as Predictors of Adverse Pathology and Biochemical Recurrence After Prostatectomy

  • Lionel L. Bañez

      Affiliations

    • Department of Surgery (Division of Urologic Surgery and Duke Prostate Center), Duke University Medical Center, Durham, North Carolina
    • Urology Section, Veterans Affairs Medical Center, Durham, North Carolina
    • Corresponding Author InformationCorrespondence: Division of Urologic Surgery and Duke Prostate Center, and Department of Surgery, Duke University Medical Center, Box 2626, MSRB-I, Suite 455, 571 Research Dr., Durham, North Carolina 27710 (telephone: 919-668-8449; FAX: 919-668-7093)
    • Financial interest and/or other relationship with AstraZeneca.
  • ,
  • Leon Sun

      Affiliations

    • Department of Surgery (Division of Urologic Surgery and Duke Prostate Center), Duke University Medical Center, Durham, North Carolina
  • ,
  • Bruce J. Trock

      Affiliations

    • Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland
  • ,
  • Misop Han

      Affiliations

    • Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland
  • ,
  • Alan W. Partin

      Affiliations

    • Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland
  • ,
  • William J. Aronson

      Affiliations

    • Urology Section, Veterans Affairs Greater Los Angeles Healthcare System and Department of Urology, University of California Los Angeles School of Medicine, Los Angeles, California
  • ,
  • Martha K. Terris

      Affiliations

    • Urology Section, Veterans Affairs Medical Center, Augusta and Section of Urology, Medical College of Georgia, Augusta, Alabama
  • ,
  • Joseph C. Presti Jr

      Affiliations

    • Urology Section, Veterans Affairs Medical Center and Department of Urology, Stanford University School of Medicine, Palo Alto, California
  • ,
  • Christopher J. Kane

      Affiliations

    • Urology Section, Veterans Affairs Medical Center, San Diego and Department of Urology, University of California San Diego, San Diego, California
  • ,
  • Christopher L. Amling

      Affiliations

    • Urology Section, Veterans Affairs Medical Center, and Department of Urology, University of Alabama, Birmingham, Alabama
  • ,
  • Judd W. Moul

      Affiliations

    • Department of Surgery (Division of Urologic Surgery and Duke Prostate Center), Duke University Medical Center, Durham, North Carolina
    • Financial interest and/or other relationship with Sanofi-Aventis, AstraZeneca and GlaxoSmithKline.
  • ,
  • Stephen J. Freedland

      Affiliations

    • Department of Surgery (Division of Urologic Surgery and Duke Prostate Center), Duke University Medical Center, Durham, North Carolina
    • Department of Pathology, Duke University Medical Center, Durham, North Carolina
    • Urology Section, Veterans Affairs Medical Center, Durham, North Carolina

Received 19 November 2008 published online 15 June 2009.

Purpose

Preoperative prostate specific antigen is widely used to predict unfavorable pathological features and biochemical relapse after radical prostatectomy. Recent reports that hemodilution may be responsible for lower prostate specific antigen in obese men led to concerns that prostate specific antigen may be less effective for prognosticating in men with increased body mass index. We determined whether the clinical usefulness of prostate specific antigen is negatively impacted by obesity by examining its operating characteristics and predictive accuracy as a function of body mass index.

Materials and Methods

We performed a multicenter retrospective analysis of the records of 11,705 men who underwent radical prostatectomy from 1988 to 2007 from Veterans Affairs hospitals of the Shared Equal Access Regional Cancer Hospital Database, the Duke Prostate Center and Johns Hopkins Hospital. ROC curve analysis, the concordance index and the test for interaction were used to compare the ability of prostate specific antigen to predict unfavorable tumor characteristics and biochemical recurrence across body mass index categories.

Results

There were no significant differences in the area under ROC curves across increasing body mass index categories for prostate specific antigen to predict pathological Gleason sum (7 or greater, 7 [4 + 3] or greater, or 8 or greater), positive surgical margins, extracapsular extension or seminal vesicle invasion in all 3 cohorts. There was no significant difference in prostate specific antigen accuracy to predict biochemical failure across increasing body mass index categories.

Conclusions

In 3 cohorts of men treated with radical prostatectomy the ability of preoperative prostate specific antigen to predict adverse pathological features and posttreatment biochemical recurrence is not significantly affected by obesity. However, adjusting for obesity related hemodilution may still be required to properly interpret prostate specific antigen results in men with increased body mass index.

Key Words: prostate, prostatic neoplasms, obesity, prostate-specific antigen, hemodilution

Abbreviations and Acronyms: BMI, body mass index, CaP, prostate cancer, PSA, prostate specific antigen, RP, radical prostatectomy, SEARCH, Shared Equal Access Regional Cancer Hospital

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Study received institutional review board approval at each institution.

 Supported by the Department of Defense Prostate Cancer Research Program, Department of Veterans Affairs, Duke University Department of Surgery and Division of Urology, an American Urological Association Foundation/Astellas Rising Star in Urology Award, National Institutes of Health Specialized Programs of Research Excellence Grants P50 CA58236 and P50 CA92131-01A1, Georgia Cancer Coalition and National Institutes of Health R01CA100938.

PII: S0022-5347(09)00892-1

doi:10.1016/j.juro.2009.04.007

The Journal of Urology
Volume 182, Issue 2 , Pages 491-498, August 2009